Literature DB >> 3167864

Specificity study to evaluate induction of aberrant crypts in murine colons.

E A McLellan1, R P Bird.   

Abstract

We have previously reported on our findings of aberrant crypts (AC) in the colons of rodents treated with a colon carcinogen. In this report, the specificity of AC formation was assessed by testing a variety of agents for their ability to induce AC in the colons of CF1 and C57BL/6J mice. In addition, the ability of each of the agents to induce nuclear aberrations (NA) was assessed and compared with the AC data. The test agents included hydrazines, polycyclic aromatic hydrocarbons, aromatic amines, and nitrosocompounds. The colons were assessed for AC 2 or 4 weeks following a single treatment with the test agent. Of the seven agents that induced AC formation, five were colon carcinogens and the other two were agents believed to be carcinogenic to organs other than the colon. None of the five agents believed to be noncarcinogens induced AC whereas three of them did induce NA in at least one of the strains of mice tested. Comparison of AC and NA induction for each test agent showed that all agents that induced AC also induced NA and that the converse was not true. The findings of the present study indicate that AC are induced specifically in response to colon carcinogens and support our contention that AC are preneoplastic lesions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3167864

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Identification of dysplasia in human colonic aberrant crypt foci.

Authors:  I M Siu; T G Pretlow; S B Amini; T P Pretlow
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Colonic aberrant crypts in azoxymethane-treated F344 rats have decreased hexosaminidase activity.

Authors:  T P Pretlow; M A O'Riordan; M F Kolman; J A Jurcisek
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

3.  Chemoprevention of tea on colorectal cancer induced by dimethylhydrazine in Wistar rats.

Authors:  Xu-Dong Jia; Chi Han
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

Review 4.  Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics.

Authors:  L Roncucci; M Pedroni; F Vaccina; P Benatti; L Marzona; A De Pol
Journal:  Cell Prolif       Date:  2000-02       Impact factor: 6.831

5.  Two types of putative preneoplastic lesions identified by hexosaminidase activity in whole-mounts of colons from F344 rats treated with carcinogen.

Authors:  T P Pretlow; M A O'Riordan; K M Spancake; T G Pretlow
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

6.  Effect of dietary fat on colonic protein kinase C and induction of aberrant crypt foci.

Authors:  L M Lafave; P Kumarathasan; R P Bird
Journal:  Lipids       Date:  1994-10       Impact factor: 1.880

7.  Induction of colonic aberrant crypts in mice by feeding apparent N-nitroso compounds derived from hot dogs.

Authors:  Michael E Davis; Michal P Lisowyj; Lin Zhou; James L Wisecarver; James M Gulizia; Valerie K Shostrom; Nathalie Naud; Denis E Corpet; Sidney S Mirvish
Journal:  Nutr Cancer       Date:  2012-01-31       Impact factor: 2.900

8.  Association between factors associated with colorectal cancer and rectal aberrant crypt foci in humans.

Authors:  Akiko Ezuka; Eiji Sakai; Kenichi Kawana; Hajime Nagase; Yukio Kakuta; Shiori Uchiyama; Hidenori Ohkubo; Takuma Higurashi; Takashi Nonaka; Hiroki Endo; Hirokazu Takahashi; Atsushi Nakajima
Journal:  Oncol Lett       Date:  2015-09-29       Impact factor: 2.967

Review 9.  Early detection of colon cancer: new tests on the horizon.

Authors:  Akshay K Gupta; Dean E Brenner; D Kim Turgeon
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 10.  Mouse models for the study of colon carcinogenesis.

Authors:  Daniel W Rosenberg; Charles Giardina; Takuji Tanaka
Journal:  Carcinogenesis       Date:  2008-11-26       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.